Efficacy and Safety of Peginterferon Alfa-2a/Ribavirin in Methadone Maintenance Patients: Randomized Comparison of Direct Observed Therapy and Self-Administration
- 1 November 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Gastroenterology
- Vol. 103 (11), 2757-2765
- https://doi.org/10.1111/j.1572-0241.2008.02065.x
Abstract
Adherence to chronic hepatitis C (CHC) treatment may be particularly challenging in methadone maintenance patients. We assessed the safety, tolerability, and efficacy of peginterferon alfa-2a/ribavirin treatment in methadone maintenance patients previously untreated for CHC. Patients were randomized 1:1 to direct observed therapy (DOT) or self-administration (SA) of peginterferon alfa-2a. DOT patients were seen weekly at methadone clinics; SA patients were seen less frequently, only at investigative sites. Genotype 1-infected patients were treated for 48 wk with peginterferon alfa-2a (180 microg/wk)/ribavirin (1,000/1,200 mg/day); genotypes 2- and 3-infected patients were treated for 24 wk with peginterferon alfa-2a (180 microg/wk)/ribavirin (800 mg/day). Based on defined efficacy stopping rules, 77% (37/48) completed their targeted length of treatment, and 44% (21/48) achieved sustained virologic response (SVR). Two DOT and 3 SA patients were withdrawn for safety reasons and 6 and 9, respectively, for nonsafety reasons. Over 60% and 50% of each group were >80% compliant with the planned cumulative doses of peginterferon alfa-2a and ribavirin, respectively, and over 60% with overall treatment duration. SVR rates were 54% (13/24) for DOT and 33% (8/24) for SA; 23% (3/13) and 38% (6/16), respectively, for genotype 1 and 91% (10/11) and 25% (2/8), respectively, for genotypes 2 and 3. Stepwise logistic regression analysis, showed that DOT (vs SA; OR 3.27, 95% CI 0.90-11.91, P = 0.073) and Caucasian race (vs Other; OR 13.31, 95% CI 1.42-124.71, P = 0.023) were predictors of SVR. Peginterferon alfa-2a/ribavirin can be used safely and successfully in CHC patients receiving methadone maintenance.Keywords
This publication has 34 references indexed in Scilit:
- Health-related quality of life in patients with chronic hepatitis C and advanced fibrosisJournal of Hepatology, 2007
- 602 Treatment of intravenous drug users (IVDU) with chronic hepatitis C: Treatment response, compliance and side effectsJournal of Hepatology, 2006
- Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapyJournal of Gastroenterology and Hepatology, 2005
- Knowledge of and interest in hepatitis C treatment at a methadone clinicJournal of Substance Abuse Treatment, 2005
- A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenanceHepatology, 2004
- Is It Justifiable to Withhold Treatment for Hepatitis C from Illicit-Drug Users?New England Journal of Medicine, 2001
- Health-related quality of life in chronic hepatitis C: Impact of disease and treatment responseHepatology, 1999
- Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapyHepatology, 1999
- Epidemiology of hepatitis CHepatology, 1997
- Successful Adherence to Observed Prophylaxis and Treatment of Tuberculosis Among Drug Users in a Methadone ProgramJournal of Addictive Diseases, 1996